ARTV Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Artiva Biotherapeutics, Inc. (ARTV)
NEW YORK CITY, NY / ACCESS Newswire / November 13, 2026 /Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) shareholders lost $1.89 per share on October 27, 2026, when the stock fell 30.68% to close at $4.27 after the Company announced it was discontinuing development of its lead cell therapy candidate. If you suffered a loss on your Artiva investment, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
The halted program was AlloNK (AB-101), Artiva 's lead allogeneic natural killer cell therapy candidate, which was being evaluated in rheumatoid arthritis and other B-cell-driven autoimmune diseases. Artiva said the decision followed a review of updated longer-term clinical data showing that the durability of clinical responses did not meet expectations. The Company also disclosed recent Grade 5 (fatal) safety events involving the deaths of two patients in its clinical studies.
Alongside the discontinuation, Artiva announced a workforce reduction of approximately 94% and said it is exploring strategic alternatives that may include a merger, an asset sale, or complete dissolution and liquidation. Levi & Korsinsky is investigating potential securities law violations on behalf of ARTV shareholders.
Investors who purchased Artiva Biotherapeutics shares and lost money can have their ARTV losses reviewed at no cost or reach Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.
Levi & Korsinsky, LLP -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Billions recovered.
Frequently Asked Questions About the ARTV Investigation
Q: What is the ARTV securities fraud investigation about?
A: A securities investigation is pending concerning Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) regarding potentially materially false or misleading statements. Shares fell approximately 30.68% after the Company disclosed the discontinuation of AlloNK (AB-101), fatal safety events, and a workforce reduction of approximately 94%, causing losses for shareholders.
Q: Who is conducting the ARTV investigation?
A: Levi & Korsinsky, LLP is investigating potential securities fraud claims on behalf of investors who purchased ARTV securities. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered billions of dollars for aggrieved investors.
Q: Who is eligible to participate in the ARTV investigation?
A: Investors who purchased ARTV stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: What do ARTV investors need to do right now?
A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.
Q: What is a lead plaintiff and why does it matter?
A: If the investigation proceeds to legal action, a lead plaintiff is the investor the court appoints to represent the group of affected investors. Lead plaintiffs are typically investors with the largest documented losses. Contacting the firm during the investigation phase preserves that option.
Q: What if I already sold my ARTV shares -- can I still recover losses?
A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought ARTV and sold at a loss may still participate in the investigation.
Q: What if my ARTV losses are small -- is it still worth contacting a lawyer?
A: Yes. There is no minimum loss amount required to participate in the investigation.
Q: What does it cost me to participate?
A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys ' fees and expenses subject to court approval.
Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
SOURCE:Levi & Korsinsky, LLP
View the original press release on ACCESS Newswire
© 2026 ACCESS Newswire. All Rights Reserved.
